Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: TheBodyPRO.com Covers AIDS 2014
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

International News

Gilead Lowers Its No-Profit Drug Prices

August 30, 2005

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!

On Monday, Gilead Sciences Inc. announced it is reducing the prices it charges developing nations for its HIV drugs Truvada and Viread. Through its access program, Gilead sells the drugs at no profit to a group of 97 developing countries. The lower prices are possible, Gilead said, thanks to increased economies of scale, a new factory in the Bahamas and manufacturing improvements that have lowered costs. The move cuts the countries' costs for Viread by 31 percent to $17 per patient per month and for Truvada by 12 percent to $26.25 per patient per month. Viread's inventors have waived their royalty rights on sales to the participating countries; Viread is contained in the combination treatment Truvada.

Back to other news for August 30, 2005

Adapted from:
Associated Press
08.29.05

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
 
See Also
More on HIV Medications
More News on Truvada (Tenofovir/FTC)

Tools
 

Advertisement